Intervention of 4% salmon phospholipid on metabolic syndrome in mice based on colonic lipidomics analysis.
BACKGROUND
The incidence of metabolic syndrome (MetS) is increasing, and n-3 polyunsaturated fatty acids (PUFAs) in salmon (Oncorhynchus) phospholipids can effectively reduce the risk of MetS.


RESULTS
Under the intervention of 4% salmon phospholipid, the levels of fasting blood glucose (FBG), insulin, monocyte chemoattractant protein-1 (MCP-1), interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) were significantly reduced in the plasma of MetS mice, whereas adiponectin was significantly increased. By screening, we found that the 18 differential metabolites, consisting of seven triglycerides (TGs), six diglycerides (DGs), one phosphatidylethanolamine (PE), three sphingomyelins (SMs) and one eicosanoid, could be the key differential metabolites, and two metabolic pathways were significantly affected: glycerolipid metabolism and glycerophospholipid metabolism.


CONCLUSION
4% salmon phospholipids could affect MetS by inhibiting insulin resistance, reducing inflammatory factors and promoting the synthesis of PE, yet the mechanism required further study. Our results could help in the treatment of MetS. © 2021 Society of Chemical Industry.
['Cao|Hui|H|', 'Chen|Shu-Fen|SF|', 'Wang|Zi-Chen|ZC|', 'Dong|Xin-Jie|XJ|', 'Wang|Ran-Ran|RR|', 'Lin|Hong|H|', 'Wang|Qi|Q|', 'Zhao|Xiu-Ju|XJ|https://orcid.org/0000-0003-4962-6285']
salmon phospholipids metabolic syndrome colonic contents pseudotargeted lipidomics